Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sudeep PharmaBOM:544619 -1.10%18 Net Margin % is 27.32% as of Mar. 2026, which is 1% below its 10-year median of 27.48. GuruFocus rates BOM:544619 with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 962 Drug Manufacturers companies, Sudeep Pharma ranks better than 92.93% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Sudeep Pharma's Net Income for the
three
months ended in Mar. 2026 was ₹489 Mil. Sudeep Pharma's Revenue for the
three
months ended in Mar. 2026 was ₹1,789 Mil. Therefore, Sudeep Pharma's net margin for the quarter that ended in Mar. 2026 was 27.32%.
The historical rank and industry rank for Sudeep Pharma's Net Margin % or its related term are showing as below:
BOM:544619'
s Net Margin % Range Over the Past 10 Years
Min: 14.62 Med: 27.48 Max: 29.29
Current: 26.74
BOM:544619's Net Margin % is ranked better than 92.93% of 962
companies
in the Drug Manufacturers industry
Industry Median: 5.37
vs BOM:544619: 26.74
Sudeep Pharma (BOM:544619) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Sudeep Pharma Net Margin % Related Terms
Sudeep Pharma Net Margin % Historical Data
* Premium members only.
The historical data trend for Sudeep Pharma's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sudeep Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sudeep Pharma Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sudeep Pharma's Net Margin % distribution charts can be found below:
* The bar in red indicates where Sudeep Pharma's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sudeep Pharma (BOM:544619) has a Net Margin % of 27.32% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Sudeep Pharma and its competitors. This is near median its historical median of 27.48. Over the past decade, Sudeep Pharma's Net Margin % has ranged from 14.62 to 29.29. According to the industry distribution chart, Sudeep Pharma ranks #68 out of 962 companies in the Drug Manufacturers industry, placing it in the top 7.1%.
Is Sudeep Pharma's Net Margin % too high?
Sudeep Pharma's current Net Margin % of 27.32% is near median its 10-year median of 27.48. Over the past 10 years, this metric has ranged from a low of 14.62 to a high of 29.29. The Drug Manufacturers industry median Net Margin % is 5.37. Sudeep Pharma's value of 27.32% is 408.8% above this industry median. Based on the distribution chart, Sudeep Pharma ranks #68 out of 962 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sudeep Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sudeep Pharma's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sudeep Pharma ranks #68 out of 962 companies for Net Margin %. This places Sudeep Pharma in the top 7% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.37. Sudeep Pharma's value of 27.32% is 408.8% above this benchmark. Historically, Sudeep Pharma's own Net Margin % has ranged from 14.62 to 29.29 over the past decade. While the company's 10-year median is 27.48 vs. the industry median of 5.37, Sudeep Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.37, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sudeep Pharma's current Net Margin % of 27.32% is 408.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Sudeep Pharma and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sudeep Pharma's current Net Margin % is 27.32%, which is near median its own 10-year median of 27.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudeep Pharma stock overvalued right now?
Sudeep Pharma (BOM:544619) has a current Net Margin % of 27.32%. The current Net Margin % is 27.32%, which is near median its 10-year median of 27.48 and 408.8% above the Drug Manufacturers industry median of 5.37. Sudeep Pharma's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Sudeep Pharma (BOM:544619), the current Net Margin % is 27.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sudeep Pharma Ltd is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries and is dedicated to contributing to the healthcare ecosystem. The company operates in two business verticals: Pharmaceutical, food, and nutrition. It focuses on providing refined, mineral-based single ingredients essential to the pharmaceutical, food, and nutrition industries and Specialty ingredients: It pertains manufacturing of specialty ingredients using advance technology solutions. The maximum revenue is generated from the Pharmaceutical, food, and nutrition segment. Geographically, it has presence in the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
18GF Score
Get the complete analysis for BOM:544619
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544619 has been successfully added to your 
